A general kinetic approach to investigation of active-site availability in macromolecular catalysts.
A potentially general kinetic method for the investigation of active-site availability in preparations of macromolecular catalysts was developed. Three kinetic models were considered: (a) the conventional two-step model of enzyme catalysis, where the preparation contains only active catalyst (E(a)) and inert (i.e. non-binding, non-catalytic) material (E(i)); (b) an extension of the conventional model (a) involving only E(a) and E(i), but with non-productive binding to E(a) (in addition to productive binding); (c) a model in which the preparation contains also binding but non-catalytic material (E(b)), predicted to be present in polyclonal catalytic antibody preparations. The method involves comparing the parameters V(max) and K(m) obtained under catalytic conditions where substrate concentrations greatly exceed catalyst concentration with those (klim/obs, the limiting value of the first-order rate constant, k(obs), at saturating concentrations of catalyst; and Kapp/m) for single-turnover kinetics, in which the reverse situation obtains. The active-site contents of systems that adhere to model (a) or extensions that also lack E(b), such as the non-productive binding model (b), may be calculated using [E(a)](T)=V(max)/klim/obs. This was validated by showing that, for alpha-chymotrypsin, identical values of [E(a)](T) were obtained by the kinetic method using Suc-Ala-Ala-Pro-Phe-4-nitroanilide as substrate and the well-known 'all-or-none' spectroscopic assay using N-trans-cinnamoylimidazole as titrant. For systems that contain E(b), such as polyclonal catalytic antibody preparations, V(max)/klim/obs is more complex, but provides an upper limit to [E(a)](T). Use of the kinetic method to investigate PCA 271-22, a polyclonal catalytic antibody preparation obtained from the antiserum of sheep 271 in week 22 of the immunization protocol, established that [E(a)](T) is less than approx. 8% of [IgG], and probably less than approx. 1% of [IgG].
Resmini
M
M
Laboratory of Structural and Mechanistic Enzymology, Department of Molecular and Cellular Biology, Queen Mary and Westfield College, University of London, Mile End Road, London E1 4NS, U.K.
Gul
S
S
Carter
S
S
Sonkaria
S
S
Topham
C M
CM
Gallacher
G
G
Brocklehurst
K
K
D000818:Animals; D017151:Antibodies, Catalytic / Q000276:immunology / Q000378:metabolism*; D001665:Binding Sites; D002384:Catalysis; D002918:Chymotrypsin / Q000378:metabolism*; D006241:Haptens / Q000737:chemistry / Q000276:immunology; D007093:Imidazoles / Q000378:metabolism; D007106:Immune Sera / Q000276:immunology / Q000378:metabolism; D007074:Immunoglobulin G / Q000276:immunology / Q000378:metabolism; D007700:Kinetics; D046911:Macromolecular Substances; D008433:Mathematics; D008956:Models, Chemical; D009842:Oligopeptides / Q000378:metabolism; D015203:Reproducibility of Results; D012756:Sheep; D013816:Thermodynamics; D017186:Titrimetry
D017151:Antibodies, Catalytic; D006241:Haptens; D007093:Imidazoles; D007106:Immune Sera; D007074:Immunoglobulin G; D046911:Macromolecular Substances; D009842:Oligopeptides; C037552:cinnamoylimidazole; C043307:succinyl-alanyl-alanyl-prolyl-phenylalanine-4-nitroanilide; D002918:Chymotrypsin; C117608:alpha-chymotrypsin